Find Funding Opportunities

The NINDS Materials to Enhance Training in Experimental Rigor (METER) UE5 will support curriculum development in the form of innovative educational materials that will be incorporated into a new cutting-edge online resource that aims to promote awareness, understanding, and practice of fundamental principles of rigorous biomedical research for researchers and other scientists in various career stages and learning environments.This UE5 FOA runs in parallel with a companion UC2 FOA that solicits applications for the NINDS center for Creating an Educational Nexus for Training in Experimental Rigor (CENTER), described in detail in RFA-NS-21-009.

This Notice announces an update to the NINDS Special Council Review (SCR) policy to exclude the pending application and set the threshold at $1.5 million in total costs per year (inclusive of direct and indirect costs). This change brings NINDS into closer alignment with NIHs implementations of SCR NOT-OD-22-049. This policy does not represent a cap on NINDS funding.

This initiative will solicit applications that propose the development and early stage validation of next generation humanized small animal models and/or human cellular microphysiological systems that improve the translational relevance of NeuroHIV models, specifically in the context of chronic HIV infection of the CNS in the modern antiretroviral therapy (ART) era under conditions of viral suppression.

This notice of opportunity announcement (NOFO) is issued by the National Institute of Neurological Disorders and Stroke to enable submission of program project grant applications that propose to conduct innovative, interactive research to answer significant scientific questions that are important for the mission of NINDS, via a synergistic collaboration between outstanding scientists who might not otherwise collaborate. The program project grant is designed to support research in which the funding of several interdependent highly meritorious projects as a group offers significant scientific advantages over support of these same projects as individual research grants.

This Notice informs potential applicants that the Key Dates information listed in PAR-24-092 has changed.

This Notice informs potential applicants that the Key Dates information listed in PAR-24-091 has changed.

The purpose of this notice is to inform applicants of an extension to PAR-21-163 Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System UG3/UH3.

Senator Paul D. Wellstone Muscular Dystrophy Specialized Research Centers (MDSRC) (P50 Clinical Trial Optional)

The purpose of this notice is to inform applications of an extension to PAR-21-153 "NINDS Faculty Development Award to Promote Diversity in Neuroscience Research (K01 Clinical Trial Required)" by one council round.

The purpose of this notice is to inform applicants of extensions to PAR-21-233 "Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System U44."